Refine
Has Fulltext
- yes (16)
Is part of the Bibliography
- yes (16)
Document Type
- Journal article (15)
- Preprint (1)
Language
- English (16)
Keywords
- gephyrin (4)
- X-ray crystallography (3)
- Cryo-EM (2)
- GABA (2)
- PIP2 (2)
- artemisinin (2)
- diazepam (2)
- inhibitory neurotransmission (2)
- AAA+ ATPase p97 (1)
- African sleeping sickness (1)
Institute
- Rudolf-Virchow-Zentrum (15)
- Institut für Pharmazie und Lebensmittelchemie (3)
- Institut für Klinische Neurobiologie (2)
- Institut für Pharmakologie und Toxikologie (2)
- Theodor-Boveri-Institut für Biowissenschaften (2)
- Institut für Organische Chemie (1)
- Institut für Physikalische und Theoretische Chemie (1)
Sonstige beteiligte Institutionen
Formation of the Aurora-A–MYCN complex increases levels of the oncogenic transcription factor MYCN in neuroblastoma cells by abrogating its degradation through the ubiquitin proteasome system. While some small-molecule inhibitors of Aurora-A were shown to destabilize MYCN, clinical trials have not been satisfactory to date. MYCN itself is considered to be `undruggable' due to its large intrinsically disordered regions. Targeting the Aurora-A–MYCN complex rather than Aurora-A or MYCN alone will open new possibilities for drug development and screening campaigns. To overcome the challenges that a ternary system composed of Aurora-A, MYCN and a small molecule entails, a covalently cross-linked construct of the Aurora-A–MYCN complex was designed, expressed and characterized, thus enabling screening and design campaigns to identify selective binders.